{
    "organizations": [],
    "uuid": "68a5b9c929d806f865ed2d26f8f8c43b7db05a3a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-xenon-pharmaceuticals-enters-into/brief-xenon-pharmaceuticals-enters-into-at-the-market-equity-offering-sales-agreement-with-stifel-nicolaus-co-idUSFWN1SF1B1",
    "ord_in_thread": 0,
    "title": "BRIEF-Xenon Pharmaceuticals Enters Into At-The-Market Equity Offering Sales Agreement With Stifel, Nicolaus & Co",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Xenon Pharmaceuticals Inc:\n* XENON PHARMACEUTICALS INC - ON MAY 8, CO ENTERED INTO AN ATâ€”MARKET EQUITY OFFERING SALES AGREEMENT WITH STIFEL, NICOLAUS & COMPANY - SEC FILING\n* XENON PHARMACEUTICALS - SALES AGREEMENT TO SELL COMMON SHARES OF CO HAVING SALES PROCEEDS OF UP TO $30 MILLION THROUGH \"AT MARKET\" EQUITY OFFERING PROGRAM Source text: ( bit.ly/2KN4M0A ) Further company coverage:\n ",
    "published": "2018-05-09T05:50:00.000+03:00",
    "crawled": "2018-05-09T12:40:14.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "xenon",
        "pharmaceutical",
        "inc",
        "xenon",
        "pharmaceutical",
        "inc",
        "may",
        "co",
        "entered",
        "equity",
        "offering",
        "sale",
        "agreement",
        "stifel",
        "nicolaus",
        "company",
        "sec",
        "filing",
        "xenon",
        "pharmaceutical",
        "sale",
        "agreement",
        "sell",
        "common",
        "share",
        "co",
        "sale",
        "proceeds",
        "million",
        "market",
        "equity",
        "offering",
        "program",
        "source",
        "text",
        "company",
        "coverage"
    ]
}